Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

tion has occurred. Consolidation or financial difficulties could cause customers to reduce their inventory levels, or otherwise reduce purchases of the Group's products. Such actions could have an adverse effect on the Group's revenues, financial condition and results of operations. A significant portion of the Group's Specialty Pharmaceuticals product sales are made to major pharmaceutical wholesale distributors as well as to large pharmacies in both the US and Europe. Consequently, product sales and growth comparisons may be affected by fluctuations in the buying patterns of major distributors and other trade buyers. These fluctuations may result from seasonality, pricing, wholesaler buying decisions, or other factors. In addition, a significant portion of the Group's revenues for certain products for treatment of rare genetic diseases are concentrated with a small number of customers. Changes in the buying patterns of those customers may have an adverse effect on the Group's financial condition and results of operations.

The outsourcing of services can create a significant dependency on third parties, the failure of whom can affect the ability to operate the Group's business and to develop and market products

The Group has entered into many agreements with third parties for the provision of services to enable it to operate its business. If the third party can no longer provide the service on the agreed basis, the Group may not be able to continue the development or commercialization of its products as planned or on a commercial basis. Additionally, it may not be able to establish or maintain good relationships with the suppliers.

The Group has also entered into licensing and co-development agreements with a number of parties. There is a risk that, upon expiration or termination of a third party agreement, the Group may not be able to renew or extend the agreement with the third party as commercial
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... As part of its 2015 growth plan and as a follow up ... business units, Whitehouse Laboratories is pleased to announce that it has begun construction on ... of Excellence and will be strictly dedicated to basic USP 51, USP 61, and USP ...
(Date:7/29/2015)... According to a new market research report, ,Global ... published by Mordor Intelligence, the Global market is expected to ... with North America being the largest ... market size. The Global market for Stem Cells is expected ... of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
(Date:7/29/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader in product ... align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and the ... of an accurate label, and pictogram uses and meanings. , “With changes to ...
Breaking Biology Technology:Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33
... , , , ... Media magazine,s 2009 Agency of the Year, today announces the opening of ... strategic part of the agency,s 2010 growth plan. Digitas Health has experienced ... last three years, 14 new client brand wins over the past 12 ...
... , , ANAHEIM, ... today and I see our company providing the technological platform for ... Pulwer, upon accepting the position of President/CEO from the Board of ... in business for over 30 years and maintains the largest installed ...
... , AUSTIN, Texas, July 27 Patton Medical ... injection port therapy, announced today that they have entered into a ... devices used in the treatment of diabetes. , , ... two companies are working together to design and develop the ...
Cached Biology Technology:Digitas Health Expands Adding Two Key Locations 2Digitas Health Expands Adding Two Key Locations 3Digitas Health Expands Adding Two Key Locations 4Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO 2Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 2Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections 3
(Date:7/31/2015)... julho de 2015 A 10 a. ... realizada pela BGI de 22-25 de outubro de 2015, em ... A conferência está celebrando seu 10 o. aniversário este ... tornou uma das reuniões mais influentes do mundo no ... dinâmicos, entusiastas e prazerosos. A ICG-10 ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale ... von BGI veranstaltet und findet vom 22. bis ... , statt. Die Konferenz ... ihrem Start 2006 ist die ICG weltweit zu ... geworden. Sie ist eines der dynamischsten, enthusiastischsten und ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... ESOF 2008 gets underway. Some major announcements before we hope to ... you have NOT registered please note: Online Registration closes June 30. ... www.esof2008.org ESOF 2008 Press briefings in Barcelona ... on Monday July 7, 11am and in Madrid Tuesday ...
... between the CSIRO/Australian Capital Ventures Limited joint venture and ... scale commercial crops of BARLEYmax unique grain ... the Director of the CSIRO Food Futures Flagship, Dr ... of insoluble and soluble fibre found in wheat or ...
... SANTA CRUZ, CA--Huge numbers of fish, seabirds, and other ... inadvertently caught during fishing operations. Known as marine bycatch, ... industry, regulatory agencies, and conservationists. One recent proposal would ... species, but a new analysis suggests that this strategy ...
Cached Biology News:New study raises concerns about proposed mitigation strategy for marine bycatch 2
... I Large (Klenow) Fragment, Exonuclease Minus, is ... the 5´→3´ and the 3´→5´ exonuclease activities ... I (1,2). It is used for random ... amplification (5). Klenow Fragment, Exonuclease Minus, will ...
... one of several isoprostanes produced from arachidonic acid ... vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 ... 0.5 and 5 µM, respectively. When infused into ... concentration of 4 mg/kg/min, 8-iso PGE2 decreases the ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... The Centra-CL5R multi-purpose centrifuge offers both ... large assortment of rotor options, making ... laboratory applications., Maximum Versatility , ... xg) angle rotors or high-volume (4 x ...
Biology Products: